Grufity logoGrufity logo
StocksFundsSearch Filings

Illumina Inc Stock Research

ILMN

195.89USD+2.36(+1.22%)Market Closed

Market Summary

USD195.89+2.36
Market Closed
1.22%

ILMN Alerts

ILMN Stock Price

ILMN RSI Chart

ILMN Valuation

Market Cap

31.0B

Price/Earnings (Trailing)

-7.03

Price/Sales (Trailing)

6.96

EV/EBITDA

-6.86

Price/Free Cashflow

-658.52

ILMN Price/Sales (Trailing)

ILMN Profitability

Operating Margin

64.83%

EBT Margin

-94.59%

Return on Equity

-66.74%

Return on Assets

-35.95%

Free Cashflow Yield

-0.15%

ILMN Fundamentals

ILMN Revenue

Revenue (TTM)

4.4B

Revenue Y/Y

-11.12%

Revenue Q/Q

0.37%

ILMN Earnings

Earnings (TTM)

-4.4B

Earnings Y/Y

-223.01%

Earnings Q/Q

96.36%

Price Action

52 Week Range

173.45258.07
(Low)(High)

Last 7 days

-4.4%

Last 30 days

-7.1%

Last 90 days

-0.4%

Trailing 12 Months

-19.6%

ILMN Financial Health

Current Ratio

1.28

ILMN Investor Care

Shares Dilution (1Y)

0.64%

Diluted EPS (TTM)

-28.51

Peers (Alternatives to Illumina)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.6B
6.9B
-9.54% -2.60%
26.94
5.14
7.53% 9.79%
31.0B
4.4B
-7.14% -19.58%
-7.03
6.96
-4.49% -677.95%
30.6B
4.0B
-7.76% 7.13%
34.48
7.74
3.66% 11.80%
15.4B
3.0B
-12.17% -18.53%
22.33
5.19
3.42% -2.23%
14.9B
3.4B
-15.95% -22.45%
15.51
4.44
-23.30% 29.82%
MID-CAP
SMALL-CAP
3.1B
128.3M
25.18% 130.68%
-9.72
24.3
-1.69% -82.99%
997.0M
184.3M
-5.67% -8.72%
-5.11
5.41
19.29% 17.33%
778.0M
104.4M
75.74% 23.16%
-9.19
7.45
-7.50% -28.77%
273.6M
132.0M
-35.71% -63.60%
-1.7
2.07
-8.69% -26.95%
248.1M
114.5M
5.19% 56.80%
-123.18
2.17
-5.10% 69.01%
195.4M
29.5M
-11.93% -58.37%
-1.4
6.62
43.94% -51.20%
164.7M
116.2M
-37.63% -75.54%
-3.44
1.42
-4.78% -132.67%
90.3M
68.7M
-6.76% -53.04%
-0.79
1.31
-13.98% -40.40%
68.1M
53.7M
0.52% -31.14%
-21.83
1.27
14.70% -1523.74%

Financials for Illumina

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-3.0%4,4474,5844,6994,6924,656
Cost Of Revenue1.5%1,6361,6121,5831,5231,452
Gross Profit-5.4%2,8112,9723,1163,1693,204
Operating Expenses1.2%7,2387,1517,1274,0683,337
  S&GA Expenses5.3%1,3661,2971,2902,0232,026
  R&D Expenses1.4%1,3391,3211,3251,4361,311
EBITDA-6.5%-4,095-3,8462441,162-
EBITDA Margin-9.1%-0.89*-0.82*0.05*0.25*-
Earnings Before Taxes-5.1%-4,555-4,336-4,0839.00853
EBT Margin-8.9%-0.95*-0.87*0.00*0.18*-
Interest Expenses57.7%41.0026.0031.0039.0049.00
Net Income-6.1%-4,404-4,152-19.00701-
Net Income Margin-8.7%-0.96*-0.88*0.00*0.15*-
Free Cahsflow-59.1%10625953.00208-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-3.6%11,81112,25211,25615,44815,274
  Current Assets-10.9%3,1723,5612,4872,8912,755
    Cash Equivalents-25.7%1,4942,0111,0001,2891,351
  Inventory3.2%586568559518465
  Net PPE-0.8%1,0821,0911,0681,0551,034
  Goodwill0%3,2393,2393,2387,1587,113
  Current Liabilities-19.6%2,2302,7732,6692,8811,490
    LT Debt, Current-499----
Shareholder's Equity1.4%6,6936,5996,73110,44410,895
  Retained Earnings0.3%1,1451,1421,2815,0975,632
  Additional Paid-In Capital1.1%9,3119,2079,1299,0338,957
Accumulated Depreciation-962----
Shares Outstanding0.6%158157157157-
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-41.3%230392527307435
  Share Based Compensation0.3%367366364790779
Cashflow From Investing3.0%-573-591-489-2,687-2,519
Cashflow From Financing-49.4%5061,000-85.00-507-998
  Buy Backs-0.00----

Risks for ILMN

What is the probability of a big loss on ILMN?

90%


Probability that Illumina stock will be more than 20% underwater in next one year

44.6%


Probability that Illumina stock will be more than 30% underwater in next one year.

22.3%


Probability that Illumina stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ILMN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Illumina was unfortunately bought at previous high price.

Drawdowns

Returns for ILMN

Cumulative Returns on ILMN

10.6%


10-Year Cumulative Returns

4.5%


7-Year Cumulative Returns

-5.9%


5-Year Cumulative Returns

-17.9%


3-Year Cumulative Returns

What are the long-term rolling returns for ILMN?

FIve years rolling returns for Illumina.

Annualized Returns

Which funds bought or sold ILMN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
BROOKFIELD Corp /ON/
sold off
-100
-2,875,490
-
-%
2023-05-23
Front Row Advisors LLC
unchanged
-
2,000
16,000
0.01%
2023-05-23
Toroso Investments, LLC
added
112
2,219,000
3,754,000
0.06%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
21,682,000
0.94%
2023-05-22
AMERIPRISE FINANCIAL INC
added
1.57
22,405,500
155,410,000
0.05%
2023-05-22
PUTNAM INVESTMENTS LLC
added
533
25,377,500
29,415,000
0.05%
2023-05-22
PUTNAM INVESTMENTS LLC
sold off
-100
-349,683
-
-%
2023-05-19
Coppell Advisory Solutions LLC
sold off
-100
-6,066
-
-%
2023-05-19
Geo Capital Gestora de Recursos Ltd
sold off
-
-
-
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
sold off
-100
-7,807,000
-
-%

1–10 of 44

Latest Funds Activity

Are funds buying ILMN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ILMN
No. of Funds

Illumina News

Nanalyze
Should You Buy Pacific Biosciences Stock Now?.
Nanalyze,
2 hours ago
GuruFocus.com
Investopedia

Schedule 13G FIlings of Illumina

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
edgewood management llc
4.1%
6,478,370
SC 13G/A
Feb 09, 2023
vanguard group inc
8.28%
13,022,627
SC 13G/A
Jan 31, 2023
blackrock inc.
7.7%
12,051,653
SC 13G/A
Jan 20, 2023
baillie gifford & co
10.64%
16,743,103
SC 13G/A
Feb 14, 2022
edgewood management llc
5.6%
8,742,202
SC 13G
Feb 03, 2022
blackrock inc.
7.5%
11,784,218
SC 13G/A
Jan 20, 2022
baillie gifford & co
13.10%
20,480,537
SC 13G/A
Feb 16, 2021
capital research global investors
0.2%
257,847
SC 13G/A
Feb 10, 2021
vanguard group inc
7.76%
11,330,232
SC 13G/A
Jan 29, 2021
blackrock inc.
7.7%
11,253,386
SC 13G/A

ILMN Fair Value

Illumina fair value in different scenarios

The table shows the Fair Value estimates for Illumina for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

35.56

-81.85%

45.85

-76.59%

61.27

-68.72%

82.03

-58.12%

94.65

-51.68%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Illumina Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Illumina

View All Filings
Date Filed Form Type Document
May 25, 2023
4
Insider Trading
May 25, 2023
4
Insider Trading
May 25, 2023
8-K
Current Report
May 24, 2023
4
Insider Trading
May 22, 2023
144
Notice of Insider Sale Intent
May 19, 2023
DFAN14A
DFAN14A
May 18, 2023
DEFA14A
DEFA14A
May 17, 2023
DEFA14A
DEFA14A
May 15, 2023
DEFA14A
DEFA14A
May 15, 2023
DFAN14A
DFAN14A

Latest Insider Trading transactions for ILMN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-22
TOUSI SUSAN H
sold
-1,042,970
208
-5,000
svp, chief commercial officer
2023-05-05
Frank John Edward
sold (taxes)
-20,764
199
-104
chief public affairs officer
2023-04-05
Pegels Kevin Carl
sold (taxes)
-28,865
230
-125
chief of global operations
2023-04-05
Rollins Carissa
sold (taxes)
-26,555
230
-115
svp, chief information officer
2023-03-31
Gottlieb Scott
acquired
21,047
210
100
-
2023-03-01
Hoyt Aimee L
acquired
-
-
6,926
svp, chief people officer
2023-03-01
TOUSI SUSAN H
acquired
-
-
10,074
svp, chief commercial officer
2023-03-01
Frank John Edward
acquired
-
-
7,556
chief public affairs officer
2023-03-01
Aravanis Alexander
acquired
-
-
10,074
svp, chief technology officer
2023-03-01
GOSWAMI JOYDEEP
acquired
-
-
10,074
svp chief financial officer

1–10 of 50

Francis A. deSouza
9800
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

ILMN Income Statement

2023-04-02
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Apr. 02, 2023
Apr. 03, 2022
Revenue:  
Total revenue$ 1,087$ 1,223
Cost of revenue:  
Amortization of acquired intangible assets4840
Total cost of revenue432408
Gross profit655815
Operating expense:  
Research and development341323
Selling, general and administrative378308
Total operating expense719631
(Loss) income from operations(64)184
Other income (expense):  
Interest income170
Interest expense(20)(6)
Other expense, net(11)(38)
Total other expense, net(14)(44)
(Loss) income before income taxes(78)140
(Benefit) provision for income taxes(81)54
Net income$ 3$ 86
Earnings per share:  
Basic (in dollars per share)$ 0.02$ 0.55
Diluted (in dollars per share)$ 0.02$ 0.55
Shares used in computing earnings per share:  
Basic (in shares)158157
Diluted (in shares)158159
Product revenue  
Revenue:  
Total revenue$ 922$ 1,070
Cost of revenue:  
Cost of revenue285299
Service and other revenue  
Revenue:  
Total revenue165153
Cost of revenue:  
Cost of revenue$ 99$ 69

ILMN Balance Sheet

2023-04-02
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Apr. 02, 2023
Jan. 01, 2023
Current assets:  
Cash and cash equivalents$ 1,494$ 2,011
Short-term investments2426
Accounts receivable, net665671
Inventory, net586568
Prepaid expenses and other current assets403285
Total current assets3,1723,561
Property and equipment, net1,0821,091
Operating lease right-of-use assets658653
Goodwill3,2393,239
Intangible assets, net3,2373,285
Other assets423423
Total assets11,81112,252
Current liabilities:  
Accounts payable242293
Accrued liabilities1,2391,232
Term notes, current portion0500
Convertible senior notes, current portion749748
Total current liabilities2,2302,773
Operating lease liabilities747744
Term notes1,4871,487
Other long-term liabilities654649
Stockholders’ equity:  
Common stock22
Additional paid-in capital9,3119,207
Accumulated other comprehensive (loss) income(1)3
Retained earnings1,1451,142
Treasury stock, at cost(3,764)(3,755)
Total stockholders’ equity6,6936,599
Total liabilities and stockholders’ equity$ 11,811$ 12,252